You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Thursday, April 21<br />
Poster Session 8:30 a.m.–5:30 p.m.<br />
P6.167 Real-World Patient Retention<br />
and Satisfaction on Fingolimod Versus<br />
Platform Injectable Disease-Modifying<br />
Therapies in Early Relapsing-Remitting<br />
Multiple Sclerosis; Results from<br />
PREFERMS —Heidi Crayton, Brian Steingo,<br />
Deren Huang, Xiangyi Meng, Lesley Schofield,<br />
Kristen Johnson, Nadia Tenenbaum<br />
P6.168 Efficacy and Tolerability of<br />
Fingolimod, Dimethylfumarate, and<br />
Teriflunomide in Patients with Multiple<br />
Sclerosis: Real World Experience from<br />
a Single Center —NgocHanh Vu, Michael<br />
Bradshaw, Harold Moses, Subramaniam<br />
Sriram, Siddharama Pawate<br />
P6.169 Early Clinical Efficacy of<br />
Fingolimod Compared with Interferon<br />
Beta-1a in Relapsing Multiple Sclerosis —<br />
Barry Singer, Daniel Ontaneda, Xiangyi Meng,<br />
Kathleen Hawker<br />
P6.170 Comparison of Baseline<br />
Characteristics of Glatiramer Acetate<br />
Versus Fingolimod in Multiple Sclerosis<br />
Patients on Brain Volume, Cognition<br />
and Neuro-QOL Outcomes: Preliminary<br />
Analysis of a Longitudinal Observational<br />
Study —Justin Honce, Kavita Nair, Brian<br />
Hoyt, Stefan Sillau, Brittany Wedeman,<br />
Eric Engebretson, Brandi Vollmer, Kristen<br />
Johnson, Nadia Tenenbaum, Vivian Herrera,<br />
Lisa Siconolfi, Augusto Miravalle, Jeffrey<br />
Bennett, John Corboy, Timothy Vollmer,<br />
Enrique Alvarez<br />
P6.171 Teriflunomide Exhibits Similar<br />
Results to Fingolimod in Number Needed<br />
to Treat Analysis —Thomas Leist, Aaron<br />
Miller, Karthinathan Thangavelu, Steven<br />
Hass, Mark Freedman<br />
P6.172 Clinical Effectiveness and<br />
Impact on Patient-Reported Outcomes<br />
of Delayed-Release Dimethyl Fumarate<br />
in Relapsing Multiple Sclerosis Patients<br />
After Suboptimal Response to Glatiramer<br />
Acetate: Six-Month Interim Analysis<br />
of a Prospective, Multicenter, Open-<br />
Label, Single-Arm, Observational Study<br />
(RESPOND)—Kiren Kresa-Reahl, Pavle<br />
Repovic, Derrick Robertson, Macaulay<br />
Okwuokenye, Leslie Meltzer, Monica Mann<br />
P6.173 Number Needed to Treat<br />
Analysis Comparing Teriflunomide<br />
and Injectable Disease-Modifying<br />
Therapies —Thomas Leist, Aaron Miller,<br />
Karthinathan Thangavelu, Steven Hass, Mark<br />
Freedman<br />
P6.174 Predictors of Long-Term<br />
Interferon Discontinuation in Newly<br />
Diagnosed Relapsing Multiple Sclerosis —<br />
Marcello Moccia, Raffaele Palladino, Roberta<br />
Lanzillo, Vincenzo Brescia Morra<br />
P6.175 Prevalence and Factors Leading<br />
to Unemployment in Immunomodulatory<br />
Treated and Untreated MS Patients in<br />
Poland - Preliminary Report —Dorota<br />
Koziarska, Danuta Nocon, Slawomir<br />
Wawrzyniak, Alina Kułakowska, Monika<br />
Adamczyk-Sowa, Król Joanna, Małgorzata<br />
Szcześniak, Przemyslaw Nowacki<br />
P6.176 Differences in Work<br />
Productivity Activity Impairment in MS<br />
Patients Initiated on Oral DMF Versus<br />
Interferon Beta or Glatiramer Acetate in<br />
Europe and the US —Ravi Iyer, Eddie Jones,<br />
Michael Edwards, Andrew Lee, James Pike<br />
P6.177 Is Severity of Adverse Events<br />
Affected by The Dose and Frequency<br />
of Glatiramer Acetate Treatment<br />
of Relapsing-Remitting Multiple<br />
Sclerosis? —Francisco Zagmutt, Ying Wu,<br />
Augusto Grinspan, Scott Kolodny, Sanjay<br />
Gandhi<br />
P6.178 Real-World Assessment of<br />
Relapse Rates in Patients with Multiple<br />
Sclerosis Newly Initiating Subcutaneous<br />
Interferon β-1a Vs Oral Disease-Modifying<br />
Drugs —Chris Kozma, Frederick Munschauer,<br />
Amy Phillips<br />
P6.179 Change in the Therapeutic<br />
Management of Multiple Sclerosis with<br />
Selective Immunosuppressants and Its<br />
Influence on the Clinical Course of the<br />
Disease —Jose E Meca-Lallana, Rocio<br />
Hernandez-Clares, Ester Carreón-Guarnizo,<br />
María Cardán-Sánchez, Cristina Sánchez-<br />
Vizcaíno Buendía, Judith Jimenez-Veiga,<br />
Adelaida Leon-Hernández, Gema Salgado-<br />
Cecilia, Jose Javier Martín-Fernández<br />
P6.180 Natalizumab, First Therapy<br />
to Demonstrate a Significant Impact on<br />
Multiple Sclerosis Disease Severity —<br />
Francois Jacques, Victorine Sikati Foko,<br />
Jacynthe Fortin<br />
P6.181 Real World Relapse Rates of<br />
Glatiramer Acetate Patients Switching to<br />
Fingolimod or Interferon Beta-1a Versus<br />
Remaining on Glatiramer Acetate —<br />
Yunfeng Li, Tara Nazareth, Huanxue Zhou,<br />
Kristen Johnson, John Ko, Kathleen Hawker,<br />
Vivian Herrera, Rahul Sasane<br />
P6.182 Longitudinal Analysis of<br />
Anti-JCV Antibody Index in Natalizumab-<br />
Treated Multiple Sclerosis Patients —Iain<br />
McGurgan, Andrew Lockhart, Michael<br />
Hutchinson, Christopher McGuigan<br />
P6.183 RRMS Patients Switching<br />
from SC IFNB-1a to Alemtuzumab in the<br />
CARE-MS I and II Extension Study Have<br />
a Reduced Rate of Brain Volume Loss —<br />
Frederik Barkhof, Jeffrey Cohen, Alasdair<br />
Coles, Edward Fox, Hans-Peter Hartung, Eva<br />
Havrdova, Krzysztof Selmaj, David Margolin,<br />
Karthinathan Thangavelu, Douglas Arnold<br />
P6.184 Safety and Efficacy of<br />
Alemtuzumab After Switching from<br />
Fingolimod: A German Multi-Center<br />
Experienceover One Year —Ralf Linker,<br />
Antonios Bayas, Anna Constantinidis,<br />
Sebastian Doerck, Kerstin Hellwig, Christoph<br />
Kleinschnitz, Ingo Kleiter, De-Hyung Lee,<br />
Mathias Maurer, Ralf Gold<br />
P6.185 Safety of Using Disease-<br />
Modifying Therapy Post-Alemtuzumab<br />
Treatment in Patients with Active<br />
Relapsing-Remitting Multiple Sclerosis in<br />
the Alemtuzumab Clinical Development<br />
Program —Ann Bass, Keith Edwards,<br />
Bhupendra Khatri, Krzysztof Selmaj, David<br />
Margolin, Linda Kasten, Per Sørensen<br />
P6.186 Patients with RRMS Who<br />
Had an Inadequate Response to a<br />
Prior Therapy Demonstrated Durable<br />
Improvement in EDSS Functional Systems<br />
Scores Over 5 Years with Alemtuzumab —<br />
Christopher LaGanke, Regina Berkovich,<br />
Oscar Fernandez, Edward Fox, Heinz Wiendl,<br />
David Margolin, Karthinathan Thangavelu,<br />
Gavin Giovannoni<br />
P6.187 Evaluating the Safety and<br />
Efficacy of Transitioning Multiple<br />
Sclerosis Patients from Natalizumab<br />
to Rituximab —James Stark, Armistead<br />
Williams, Saud Sadiq<br />
P6.188 4 Years PANGAEA: Long Term<br />
Data on Effectiveness and Safety from<br />
Patients on Natalizumab Switching to<br />
Fingolimod in Real World —Tjalf Ziemssen,<br />
Holger Albrecht, Judith Haas, Luisa Klotz,<br />
Michael Lang, Chrstoph Lassek, Stephan<br />
Schmidt, Bjorn Tackenberg, Christian<br />
Cornelissen<br />
P6.189 Predictive Value of Early MRI<br />
Measures for Long-Term Disease Activity<br />
in Patients with Relapsing-Remitting<br />
Multiple Sclerosis Receiving IFN β-1a SC<br />
Tiw or IFN β-1a IM Qw: Post Hoc Analyses<br />
of the EVIDENCE Study —Patricia Coyle,<br />
Mark Freedman, Fernando Dangond, Juanzhi<br />
Fang, Anthony Reder<br />
P6.190 MRI Frequency and No<br />
Evidence of Disease Activity Status<br />
Among Patients with RRMS Receiving IFN<br />
β-1a SC Tiw or IFN β-1a IM Qw: Post Hoc<br />
Analyses of EVIDENCE —Anthony Reder,<br />
Mark Freedman, Juanzhi Fang, Fernando<br />
Dangond, Patricia Coyle<br />
P6.191 Effects of Multiple Sclerosis<br />
Therapies on the Gut Immune System —<br />
Katja Thomas, Tjalf Ziemssen, Judith Eisele,<br />
Heinz Reichmann<br />
P6.192 Dimethyl Fumarate-Associated<br />
Lymphopenia in Clinical Practice:<br />
Implications for Disease Modifying<br />
Therapy Selection —Jessica Robb, Megan<br />
Hyland, Lawrence Samkoff<br />
Behavioral and Cognitive Neurology:<br />
Assessment Tools<br />
P6.193 Cerebrovascular Risk Factors<br />
and Depression: Report from National<br />
Ambulatory Medical Care Survey<br />
2002-2009 —Hossam Egila, Basit Rahim,<br />
Muhammad Suri, Adnan Qureshi<br />
P6.194 Validation of the AWOL Tool: A<br />
Delirium Prediction Rule —Ethan Brown, S.<br />
Josephson, Vanja Douglas<br />
P6.195 The Neuropsychiatric Inventory<br />
Questionnaire (NPI-Q2): Comparative<br />
Data in Alzheimer Disease, Lewy<br />
Body Dementia, and Frontotemporal<br />
Degeneration —Lydia Hatfield, Jennifer<br />
Taylor, James Bateman, Matthew Harris,<br />
Daniel Kaufer<br />
P6.196 Effect of a Comprehensive<br />
Inpatient Delirium Care Pathway on<br />
Incidence and Length of Stay —Ethan<br />
Brown, S. Josephson, Noriko Anderson, Mary<br />
Reid, Vanja Douglas<br />
P6.197 Durability of Symptom<br />
Reductions Associated with Use of<br />
HIRREM by Military Personnel with<br />
Traumatic Stress —Charles Tegeler,<br />
Catherine Tegeler, Jared Cook, Lindsay<br />
Howard, Sung Lee, Hossam Shaltout<br />
P6.198 Perioperative Rivastigmine<br />
Patch Reduces Occurrence of<br />
Postoperative Delirium in Elderly at Risk<br />
for Dementia —Youn Young Chul, Ha Yong-<br />
Chan, Byung-Sun Choi<br />
P6.199 Is Olanzapine Predicted to<br />
Have Antidepressant Effects on Juvenile<br />
Rats in the Forced Swim Test (FST)?—<br />
Alicia Cho, Erica Stanley, David Middlemas<br />
P6.200 Lesion-Related Delusional<br />
Misidentification Syndromes: A Review<br />
of All Reported Cases —Richard Darby,<br />
Sashank Prasad<br />
P6.201 Voxel-based Morphometry<br />
of Patients with Schizophrenia and<br />
Schizoaffective Disorders —Johnathon<br />
Shaffer, Jeiran Choupan, Bryan Mowry,<br />
Zhengyi Yang, David Reutens<br />
P6.202 Involvement of Subthalamic<br />
Neurons in Valence Processing and<br />
Impulsivity in Parkinson’s Disease —Justin<br />
Rossi, Jonathan Shute, Rene Molina, Enrico<br />
Opri, Oscar Castellanos, Corinna Peden, Kelly<br />
Foote, Aysegul Gunduz, Michael Okun<br />
Behavioral and Cognitive Neurology:<br />
Brain-behavior Correlations<br />
P6.203 Delayed Post Hypoxic<br />
Leukoencephalopathy Following<br />
Benzodiazepine and Opiate Overdose:<br />
A Case Report and Review of Disease<br />
Pathophysiology —Dionne Swor, Frank<br />
Sharp, Glen Jickling, Benjamin Koo<br />
P6.204 Verbal Memory and Processing<br />
Speed Deficits in Middle-Aged Individuals<br />
with Type 2 Diabetes Mellitus — María<br />
Beatriz Jurado, Michael Palacios, Ibeth<br />
Regato-Ugalde, Carlos Cevallos, Ximena<br />
Gamboa, Daniel Moreno-Zambrano, Carlos<br />
Peñaherrera, María Carolina Duarte,<br />
Leonardo Tamariz, Rocío Santibáñez<br />
P6.205 Cognitive Reserve in Primary<br />
Age-Related Tauopathy —Kyra Jefferson-<br />
George, Edward Lee, David Wolk, Corey<br />
McMillan<br />
P6.206 Digital Versus Paper Self-<br />
Administered Gerocognitive Examination<br />
(SAGE) —Douglas Scharre, Shu-Ing Chang,<br />
Haikady Nagaraja, Nicole Vrettos<br />
P6.207 Reduced Tactile Pressure<br />
Perception with Age —Tigran Kesayan,<br />
Damon Lamb, John Williamson, Adam<br />
Falchook, Kenneth Heilman<br />
P6.208 Hyperfamiliarity in Dementia<br />
and Mild Cognitive Impairment —Simon<br />
Kang Seng Ting, Wahab Hameed, Kathryna<br />
Kwok, Christopher Gabriel, Kinjal Doshi, Sze<br />
Yan Tay, Stephanie Fook-Chong, Sharon Koh,<br />
Way Inn Koay<br />
P6.209 Encephalitis in the Elderly:<br />
NMDA-R Encephalitis Mistaken for<br />
Dementia —Ashhar Ali, Eric Baron<br />
P6.210 Knowledge Translation in Right<br />
Brain Rehabilitation: A Feasibility Study of<br />
Prism Treatment After Acute Stroke —A.<br />
Barrett, Peii Chen, Kimberly Hreha, Florence<br />
Alban, Cynthia Gocon, Christopher Santos,<br />
Kevin Lawless, Jennifer LaRosa<br />
138 2016 AAN Annual Meeting Abstract Listing
Change language